CANCER:

Endometrial Cancer

Related cancers:

‹

›

No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval FDA - 2 weeks
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	dostarlimab Sensitive: A1 - Approval
HER-2 expression HER-2 expression	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Endometrial Cancer Endometrial Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Endometrial Cancer Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	cisplatin + paclitaxel + SGN-15 Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Endometrial Cancer Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	docetaxel Sensitive: A2 - Guideline
HER-2 positive HER-2 positive	Endometrial Cancer Endometrial Cancer	trastuzumab Sensitive: A2 - Guideline
TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	cisplatin + ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	paclitaxel + ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	ifosfamide Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	topotecan Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	cisplatin + SGN-15 Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	SGN-15 Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	carboplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	cisplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	bevacizumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Endometrial Cancer Endometrial Cancer	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Endometrial Cancer Endometrial Cancer	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	tamoxifen + medroxyprogesterone Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	tamoxifen Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	fulvestrant Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	Aromatase inhibitor Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	medroxyprogesterone Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	megestrol Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	tamoxifen + megestrol Sensitive: A2 - Guideline
No biomarker No biomarker	Endometrial Cancer Endometrial Cancer	everolimus + letrozole Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: B - Late Trials
CTNNB1 mutation CTNNB1 mutation	Endometrial Cancer Endometrial Cancer	PRI-724 + SM04690 Sensitive: B - Late Trials
CTNNB1 mutation CTNNB1 mutation	Endometrial Cancer Endometrial Cancer	SM04690 Sensitive: B - Late Trials
HER-2 overexpression HER-2 overexpression	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label
HER-2 positive HER-2 positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	olaparib Sensitive: C1 - Off-label
BRCA2 mutation BRCA2 mutation	Endometrial Cancer Endometrial Cancer	olaparib Sensitive: C1 - Off-label
KRAS G12C KRAS G12C	Endometrial Cancer Endometrial Cancer	sotorasib Sensitive: C1 - Off-label
KIT expression KIT expression	Endometrial Cancer Endometrial Cancer	imatinib Sensitive: C1 - Off-label
HER-2 overexpression HER-2 overexpression	Endometrial Cancer Endometrial Cancer	trastuzumab Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	niraparib Sensitive: C1 - Off-label
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	INCMGA0012 Sensitive: C2 – Inclusion Criteria
ER positive ER positive	Endometrial Cancer Endometrial Cancer	ribociclib + letrozole Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria
FGFR2 S252W FGFR2 S252W	Endometrial Cancer Endometrial Cancer	ponatinib Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Endometrial Cancer Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria
POLE mutation POLE mutation	Endometrial Cancer Endometrial Cancer	avelumab Sensitive: C2 – Inclusion Criteria
HER-2 amplification HER-2 amplification	Endometrial Cancer Endometrial Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria
MSI-H/dMMR MSI-H/dMMR	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	AZD1775 Sensitive: C3 – Early Trials
HER-2 positive HER-2 positive	Endometrial Adenocarcinoma Endometrial Adenocarcinoma	trastuzumab Sensitive: C3 – Early Trials
ER positive ER positive	Endometrial Cancer Endometrial Cancer	palbociclib + letrozole Sensitive: C3 – Early Trials
DKK1 overexpression DKK1 overexpression	Endometrial Cancer Endometrial Cancer	DKN-01 Sensitive: C3 – Early Trials
MCL1 amplification MCL1 amplification	Endometrial Cancer Endometrial Cancer	CYC065 Sensitive: C3 – Early Trials
KRAS G12C KRAS G12C	Endometrial Cancer Endometrial Cancer	MRTX849 Sensitive: C3 – Early Trials
ATM PI2629fs* ATM PI2629fs*	Endometrial Cancer Endometrial Cancer	BAY1895344 Sensitive: C3 – Early Trials
FOLR1 expression FOLR1 expression	Endometrial Cancer Endometrial Cancer	IMGN 853 Sensitive: C3 – Early Trials
PD-L1 expression PD-L1 expression	Endometrial Cancer Endometrial Cancer	AB122 Sensitive: C3 – Early Trials
TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	AB122 Sensitive: C3 – Early Trials
POLE V411L POLE V411L	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials
POLE P286R POLE P286R	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials
PTEN mutation PTEN mutation	Endometrial Cancer Endometrial Cancer	LY3023414 Sensitive: C3 – Early Trials
PIK3R1 mutation PIK3R1 mutation	Endometrial Cancer Endometrial Cancer	LY3023414 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	VS-6766 Sensitive: C3 – Early Trials
PTEN-L PTEN-L	Endometrial Cancer Endometrial Cancer	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	cobimetinib + GDC-0068 Sensitive: C3 – Early Trials
HER-2 expression HER-2 expression	Endometrial Cancer Endometrial Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
AKT1 mutation AKT1 mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials
CTNNB1 mutation CTNNB1 mutation	Endometrial Cancer Endometrial Cancer	everolimus + letrozole Sensitive: C3 – Early Trials
CTNNB1 mutation CTNNB1 mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials
EGFR E690K EGFR E690K	Endometrial Cancer Endometrial Cancer	lapatinib Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Endometrial Cancer Endometrial Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
KRAS mutation KRAS mutation	Endometrial Cancer Endometrial Cancer	BGB-283 Sensitive: C3 – Early Trials
PTEN deletion PTEN deletion	Endometrial Cancer Endometrial Cancer	olaparib Sensitive: C3 – Early Trials
TSC1 mutation TSC1 mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials
TSC2 mutation TSC2 mutation	Endometrial Cancer Endometrial Cancer	temsirolimus Sensitive: C3 – Early Trials
FGFR2-BICC1 fusion FGFR2-BICC1 fusion	Endometrial Cancer Endometrial Cancer	erdafitinib Sensitive: C3 – Early Trials
FGFR2-OFD1 fusion FGFR2-OFD1 fusion	Endometrial Cancer Endometrial Cancer	erdafitinib Sensitive: C3 – Early Trials
LRP1B mutation LRP1B mutation	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: C3 – Early Trials
LRP1B mutation LRP1B mutation	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Endometrial Cancer Endometrial Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 overexpression HER-2 overexpression	Endometrial Cancer Endometrial Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials
HER-2 amplification HER-2 amplification	Endometrial Cancer Endometrial Cancer	pyrotinib Sensitive: C3 – Early Trials
MSH2 deletion MSH2 deletion	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials
MLH1 deletion MLH1 deletion	Endometrial Cancer Endometrial Cancer	nivolumab Sensitive: C3 – Early Trials

Endometrial Cancer

Associations(164)

Associations
(164)